Dyadic International (DYAI) Projected to Release Earnings on Thursday

Dyadic International (NASDAQ:DYAI) is anticipated to post its Q3 2026 results after the market closes on Thursday, November 12th. Analysts expect Dyadic International to announce earnings of ($0.03) per share and revenue of $1.43 million for the quarter. Interested persons may review the information on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 12, 2026 at 5:00 PM ET.

Dyadic International (NASDAQ:DYAI) last issued its quarterly earnings results on Wednesday, August 12th. The biotechnology company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.02). Dyadic International had a negative return on equity of 2,920.31% and a negative net margin of 201.43%. The business had revenue of $0.96 million during the quarter, compared to analyst estimates of $1.02 million. On average, analysts expect Dyadic International to post ($0.15) EPS for the current fiscal year and ($0.08) EPS for the next fiscal year.

Dyadic International Stock Performance

Shares of DYAI stock opened at $0.37 on Wednesday. Dyadic International has a fifty-two week low of $0.33 and a fifty-two week high of $1.60. The firm has a market capitalization of $14.66 million, a price-to-earnings ratio of -1.59 and a beta of 1.10. The stock’s 50-day simple moving average is $0.43 and its 200-day simple moving average is $0.74.

Wall Street Analyst Weigh In

Separately, Weiss Ratings lowered shares of Dyadic International from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, October 16th. One research analyst has rated the stock with a Sell rating. According to data from MarketBeat, Dyadic International has a consensus rating of “Sell”.

About Dyadic International

Dyadic International, Inc. is a biotechnology company focused on developing and commercializing microbial protein-expression technologies for the production of biologic products. Its platforms are designed to enable the efficient development and manufacture of proteins used in vaccines, therapeutics, food and nutrition products, and industrial applications. The company’s principal technology, the C1 expression platform, is based on a proprietary strain of the fungus Trichoderma reesei . Dyadic has also developed additional microbial systems, including the Dapibus platform, which is intended to support the production of proteins and other biological materials in yeast.